Safety and Immunogenicity of First Russian Quadrivalent (Recombinant, Adsorbed) Human Papillomavirus (Types 6, 11, 16, 18) Vaccine in Children Aged 9–17 Years: Multicenter, Randomized, Double-Blind, Phase III Clinical Trial
Background . Human papillomavirus (HPV) infection is a significant risk factor for the development of HPV-associated precancerous and malignant diseases. Recombinant adsorbed vaccine against HPV (types 6, 11, 16, and 18) has been developed in Russian Federation to prevent these conditions. Vaccine immunogenicity and...